GSK has announced it is further expanding its vaccines presence in the U.S. by establishing a new global center for vaccines R&D in Rockville, Maryland.

The new site will become one of three global vaccines R&D centers for GSK, complementing the company’s existing global R&D sites in Rixensart, Belgium and in Siena, Italy, a site which GSK acquired from Novartis as part of an asset swap deal that originated last April.

According to the GSK press release, the initiative will "consolidate vaccines R&D activities currently conducted at other GSK sites including in Philadelphia, PA and Cambridge, MA, into one centralized location."